Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

N. M. Tannir; A. Naing; K. P. Papadopoulos; D. J. Wong; W. M. Korn; R. Aljumaily; K. A. Autio; S. Pant; T. M. Bauer; A. Drakaki; N. Daver; A. Hung; M. Oft; J. Leveque

doi:10.1093/annonc/mdy288.003

Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

N. M. Tannir, A. Naing, K. P. Papadopoulos, D. J. Wong, W. M. Korn, R. Aljumaily, K. A. Autio, S. Pant, T. M. Bauer, A. Drakaki, N. Daver, A. Hung, M. Oft, J. Leveque

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	viii401
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy288.003
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy288.003

Cite this

Tannir, N. M., Naing, A., Papadopoulos, K. P., Wong, D. J., Korn, W. M., Aljumaily, R., Autio, K. A., Pant, S., Bauer, T. M., Drakaki, A., Daver, N., Hung, A., Oft, M., & Leveque, J. (2018). Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii401. https://doi.org/10.1093/annonc/mdy288.003

Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors. / Tannir, N. M.; Naing, A.; Papadopoulos, K. P. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii401.

Research output: Contribution to journal › Article › peer-review

Tannir, NM , Naing, A, Papadopoulos, KP, Wong, DJ, Korn, WM, Aljumaily, R, Autio, KA, Pant, S, Bauer, TM, Drakaki, A, Daver, N, Hung, A, Oft, M & Leveque, J 2018, 'Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii401. https://doi.org/10.1093/annonc/mdy288.003

@article{c024107bfffb44e38d335dc50555bfd7,

title = "Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors",

author = "Tannir, {N. M.} and A. Naing and Papadopoulos, {K. P.} and Wong, {D. J.} and Korn, {W. M.} and R. Aljumaily and Autio, {K. A.} and S. Pant and Bauer, {T. M.} and A. Drakaki and N. Daver and A. Hung and M. Oft and J. Leveque",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy288.003",

language = "English (US)",

volume = "29",

pages = "viii401",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

AU - Tannir, N. M.

AU - Naing, A.

AU - Papadopoulos, K. P.

AU - Wong, D. J.

AU - Korn, W. M.

AU - Aljumaily, R.

AU - Autio, K. A.

AU - Pant, S.

AU - Bauer, T. M.

AU - Drakaki, A.

AU - Daver, N.

AU - Hung, A.

AU - Oft, M.

AU - Leveque, J.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85062764500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062764500&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy288.003

DO - 10.1093/annonc/mdy288.003

M3 - Article

C2 - 32137005

SN - 0923-7534

VL - 29

SP - viii401

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this